Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation
This study is testing an experimental anti-cancer drug called CX-5461 in people with advanced solid tumors. Researchers want to find the safest and most effective dose of this medicine to help fight cancer.
You may be able to join if you have a confirmed diagnosis of breast, prostate, pancreas, or ovarian cancer with specific genetic mutations like BRCA or PALB2. There are also health and safety guidelines, such as not having untreated brain metastases.
Participants will receive the study drug through an intravenous infusion into the vein on certain days of a 28-day cycle. Doctors will closely monitor your safety, how your body responds to the treatment, and your overall quality of life.
This study is currently recruiting participants at multiple locations across the United States, including California, Florida, and Massachusetts.
- 1Testing a new cancer drug called CX-5461
- 2Requires specific genetic mutations like BRCA or PALB2
- 3Currently recruiting patients at select medical centers in the US
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.